CONCLUSIONS
PD‐L1
STAGE II NSCLC, ADVERSE EVENTS
Only 56% of patients treated at our centres with concurrent chemoradiotherapy for stage III NSCLC met the eligibility criteria for the PACIFIC trial. Trial‐eligible patients had improved prognosis irrespective of durvalumab. A subset of ineligible patients who received durvalumab did not have worse outcomes or increased adverse events compared to trial‐eligible patients. The decision to proceed with durvalumab treatment in patients following chemoradiation should be individualized. Further studies are needed to explore the relationship of PD‐L1 expression and benefit from durvalumab.